Radioimmunoassay Market About To Generate Revenue worth $428.4 Million by 2020

The report "Radioimmunoassay Market by Type (Reagents & Kits, Analyzers), End User (Hospital, Pharmaceutical Industry, Academics, Clinical Diagnostic Labs), Application (Research, Clinical Diagnostics), and Geography - Global Forecast to 2020", the global radioimmunoassay (RIA) market was valued at $345.2 Million in 2014 and is expected to reach $428.4 Million by 2020, at a CAGR of 3.5% during the forecast period from 2015 to 2020.

Browse 75 market data Tables and 68 Figures spread through 113 Pages and in-depth TOC on "Radioimmunoassay Market"
Early buyers will receive 10% customization on this report.

The technique of radioimmunoassay is basically used to measure the concentration of specific antigens by using specific antibodies. This technique is mainly used for research purposes rather than diagnostics purposes. This market constituted 2.3% share of the global immunoassay market.

Radioimmunoassay has applications in the field of clinical diagnostics, and is used in hospitals, contract research organizations (CRO), laboratories, pharmaceutical companies, and others. It is used for the early detection and diagnosis of cancer, recognition of endocrinological disorders, and various other applications. Pharmaceuticals companies use the RIA techniques for medicine and drug testing. Radioimmunoassay also has its application in the research purposes, and this segment contributed a share of 65.9% to the overall market in 2014.

Get The Sample Copy Of This Report:

Over the years, there has been a significant growth in the utilization of radioimmunoassay technique in Europe owing to the advancements in medical research, clinical trials, and pharmaceutical industries. Over the next five years, the growth in the Asian radioimmunoassay market is expected to be centered in China, India, and Japan. The European radioimmunoassay market contributed the largest share in the global market, and was valued at $121.5 million in 2014. It is projected to reach $154.6 million by 2020, at a CAGR of 3.9% during the given forecast period. The limitations of the global RIA market are its high cost; government restrictions; and continuous innovations in the biomedical research for other immunoassay techniques, such as enzyme-linked immunosorbent assay (ELISA) kits. Major companies operational in the radioimmunoassay market are DIAsource ImmunoAssays SA (Europe), Immunotec Inc. (Canada), and DIAsource ImmunoAssay S.A.(Europe).

Some of the major players in the global radioimmunoassay market are DIAsource ImmunoAssays SA (Belgium), Beckman Coulter, Inc. (U.S.), IBL International (A Tecan Company) (Germany), PerkinElmer, Inc. (U.S.), DRG International, Inc. (U.S.), MP Biomedicals, LLC (U.S.), Cisbio (France), Euro Diagnostica AB (Sweden), DiaSorin S.p.A.. (Italy), EMD Millipore (U.S.), Izotop (Hungary), Berthold Technologies GmbH & Co. KG (Germany), and Stratec Biomedical AG (Germany).

Talk to Our Research Analysts for More Info@

The research study is aimed at identifying emerging trends and opportunities in the global radioimmunoassay market along with detailed classifications, in terms of revenue. It provides comprehensive competitive landscape and identifies the key players with respect to market size and market share. The research study also includes a detailed segmentation of the global radioimmunoassay (RIA) market on the basis of type, application, end user, and geography.

Apart from the market segmentation, this report also makes use of the Porter’s Five Forces Analysis, which provides an in-depth analysis of the market by providing a detailed process flow diagram and market dynamics, such as drivers, restraints, and opportunities in the global radioimmunoassay market.

Browse Related Reports:
Immunoassay Market
by Technology (ELISA, Fluorescence, Colorimetric, Chemiluminescence, Rapid Test, Western Blot, ELISPOT, PCR), Application (Infectious Disease, Endocrinology, Cardiology, Oncology, Hematology), & End User - Global Forecast to 2019.

Blood Screening Market by Technology (Nucleic Acid Amplification Test, ELISA, Rapid Test, Chemiluminescence Immunoassay, Next Generation Sequencing, Western Blotting), Product (Instrument, Reagent) & End User (Blood Bank, Hospital) - Forecasts to 2019.

About MarketsandMarkets:
MarketsandMarkets is world’s No. 2 firm in terms of annually published premium market research reports. Serving 1700 global fortune enterprises with more than 1200 premium studies in a year, M&M is catering to multitude of clients across 8 different industrial verticals. We specialize in consulting assignments and business research across high growth markets, cutting edge technologies and newer applications. Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors.

M&M’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. The new included chapters on Methodology and Benchmarking presented with high quality analytical infographics in our reports gives complete visibility of how the numbers have been arrived and defend the accuracy of the numbers.

We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.

Subscribe Reports from Healthcare Domain @

Mr. Rohan
Unit No. 802, 8th Floor,
Tower - 7, Magarpatta City SEZ,
Hadapsar, Pune – 411013,
Maharashtra, India.
Tel: +1-888-6006-441.
Visit MarketsandMarkets Blog @
Connect with us on LinkedIn @